These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 12424067)

  • 1. Management of malignant gastrointestinal stromal tumours.
    Joensuu H; Fletcher C; Dimitrijevic S; Silberman S; Roberts P; Demetri G
    Lancet Oncol; 2002 Nov; 3(11):655-64. PubMed ID: 12424067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate.
    Koh JS; Trent J; Chen L; El-Naggar A; Hunt K; Pollock R; Zhang W
    Histol Histopathol; 2004 Apr; 19(2):565-74. PubMed ID: 15024716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
    Demetri GD
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.
    Demetri GD
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1115-24. PubMed ID: 12512386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review.
    Miettinen M; El-Rifai W; H L Sobin L; Lasota J
    Hum Pathol; 2002 May; 33(5):478-83. PubMed ID: 12094372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal stromal tumors: rationale for surgical adjuvant trials with imatinib.
    Cormier JN; Patel SR; Pisters PW
    Curr Oncol Rep; 2002 Nov; 4(6):504-9. PubMed ID: 12354363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal stromal tumors (GIST): a model for molecule-based diagnosis and treatment of solid tumors.
    Kitamura Y; Hirota S; Nishida T
    Cancer Sci; 2003 Apr; 94(4):315-20. PubMed ID: 12824897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal stromal tumors: chemotherapy and imatinib.
    Muler JH; Baker L; Zalupski MM
    Curr Oncol Rep; 2002 Nov; 4(6):499-503. PubMed ID: 12354362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal stromal tumours.
    Connolly EM; Gaffney E; Reynolds JV
    Br J Surg; 2003 Oct; 90(10):1178-86. PubMed ID: 14515284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal stromal tumors--a review.
    Joensuu H; Kindblom LG
    Acta Orthop Scand Suppl; 2004 Apr; 75(311):62-71. PubMed ID: 15188667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571).
    DeMatteo RP
    Ann Surg Oncol; 2002 Nov; 9(9):831-9. PubMed ID: 12417503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL; Fletcher CD
    Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors.
    Eisenberg BL
    Oncology (Williston Park); 2003 Nov; 17(11):1615-20; discussion 1620, 1623, 1626 passim. PubMed ID: 14682111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?
    Scaife CL; Hunt KK; Patel SR; Benjamin RS; Burgess MA; Chen LL; Trent J; Raymond AK; Cormier JN; Pisters PW; Pollock RE; Feig BW
    Am J Surg; 2003 Dec; 186(6):665-9. PubMed ID: 14672776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.
    de Jong FA; Verweij J
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):757-66. PubMed ID: 14686698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
    Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib.
    de Silva CM; Reid R
    Pathol Oncol Res; 2003; 9(1):13-9. PubMed ID: 12704441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of gastrointestinal stromal tumors in the era of tyrosine kinase inhibitors.
    George S; Desai J
    Curr Treat Options Oncol; 2002 Dec; 3(6):489-96. PubMed ID: 12392638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.